<DOC>
	<DOCNO>NCT01107951</DOCNO>
	<brief_summary>The purpose study determine response rate response duration combination low-dose rituximab high-dose dexamethasone treatment adult immune thrombocytopenic purpura .</brief_summary>
	<brief_title>Low-dose Rituximab High-dose Dexamethasone First Line Treatment ITP</brief_title>
	<detailed_description>ITP autoimmune disorder characterize formation autoantibody platelet antigen lead platelet destruction bleeding . Corticosteroids increase platelet count 80 percent patients.However , many patient relapse dose corticosteroid reduce . Debilitating side effect common patient require long-term corticosteroid therapy maintain platelet count . Rituximab , chimeric anti-CD20 monoclonal antibody , show effectively raise platelet count patient ITP clinical biological evidence suggest , give early , rituximab may prevent ITP relapse . Rituximab 375 mg/m2 weekly four week significant activity patient immune thrombocytopenia . Furthermore , use low dose rituximab level B-cell depletion response rate appear similar previously observe standard dosage population ITP . The purpose study determine response rate response duration combination low-dose rituximab ( 100mg IV day 1,8 , 15 22 ) high-dose dexamethasone ( 40mg PO day 1,2,3,4 ) untreated adult patient immune thrombocytopenic purpura . A complete platelet response define increase platelet count &gt; 150×109/L two consecutive occasion . A partial response define increase platelet count 50 150×109/L two consecutive occasion , 1 week apart . Duration response consider day initial infusion first time relapse ( platelet count &lt; 30×109/L ) time analysis .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Clinically confirm immune thrombocytopenic purpura ( ITP ) Platelet count le 30,000/mm3 two occasion . Platelets &gt; 30000/mm3 bleeding . Normal increase number megakaryocytes bone marrow examination patient ≥ 60 year Subject ≥ 18 year Subject sign dated write informed consent . No sepsis fever No active infection require therapy No active chronic viral infection HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Performance status equal 2 . Previous treatment rituximab Immunosuppressive treatment within last month Previous splenectomy Presence malignant haematological disease Connective tissue disease Autoimmune hemolytic anemia Pregnancy lactation Not willing participate study . Expected survival &lt; 2 year Known intolerance murine antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Low-dose</keyword>
	<keyword>ITP</keyword>
</DOC>